Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $436.00 at Robert W. Baird

Intuitive Surgical (NASDAQ:ISRG) had its price target lowered by Robert W. Baird from $440.00 to $436.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

ISRG has been the subject of several other research reports. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a buy rating in a research note on Monday, April 8th. Raymond James boosted their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an outperform rating in a research note on Thursday, January 25th. Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a hold rating in a research note on Friday. Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an overweight rating in a research note on Friday, January 19th. Finally, Citigroup boosted their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $396.17.

Intuitive Surgical Stock Down 1.7 %

ISRG opened at $366.34 on Friday. The stock has a market cap of $129.85 billion, a PE ratio of 66.13, a price-to-earnings-growth ratio of 5.78 and a beta of 1.36. The company has a fifty day moving average of $386.84 and a 200-day moving average of $343.10. Intuitive Surgical has a twelve month low of $254.85 and a twelve month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 13.27%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.00 earnings per share. Sell-side analysts anticipate that Intuitive Surgical will post 4.93 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 20,296 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,168,656.60. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock worth $95,927,097 in the last three months. 0.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently modified their holdings of ISRG. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 30,375,494 shares of the medical equipment provider’s stock worth $10,247,477,000 after acquiring an additional 507,267 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after acquiring an additional 272,741 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Intuitive Surgical by 1.0% in the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock worth $1,642,287,000 after acquiring an additional 61,659 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Intuitive Surgical by 29.9% in the fourth quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock worth $1,556,706,000 after buying an additional 1,351,002 shares during the last quarter. Finally, Edgewood Management LLC boosted its holdings in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after buying an additional 374,667 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.